Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS.

Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4.

PMID:
20610349
2.

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F.

Mult Scler. 2014 Apr;20(5):577-87. doi: 10.1177/1352458513503597.

PMID:
24009164
3.

Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.

Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G.

Mult Scler. 2011 Nov;17(11):1333-40. doi: 10.1177/1352458511412654.

PMID:
21685230
4.

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.

Pachner AR, Warth JD, Pace A, Goelz S; INSIGHT investigators..

Neurology. 2009 Nov 3;73(18):1493-500. doi: 10.1212/WNL.0b013e3181bf98db. Erratum in: Neurology. 2010 Mar 16;74(11):936.

PMID:
19884577
5.

Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.

Bertolotto A, Capobianco M, Amato MP, Capello E, Capra R, Centonze D, Di Ioia M, Gallo A, Grimaldi L, Imberti L, Lugaresi A, Mancinelli C, Marrosu MG, Moiola L, Montanari E, Romano S, Musu L, Paolicelli D, Patti F, Pozzilli C, Rossi S, Salvetti M, Tedeschi G, Tola MR, Trojano M, Zaffaroni M, Malucchi S; Italian Multiple Sclerosis Study group..

Neurol Sci. 2014 Feb;35(2):307-16. doi: 10.1007/s10072-013-1616-1. Erratum in: Neurol Sci. 2014 Oct;35(10):1645-6. Troiano, Maria [corrected to Trojano, Maria].

PMID:
24374787
6.

One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.

Malucchi S, Gilli F, Caldano M, Sala A, Capobianco M, di Sapio A, Granieri L, Bertolotto A.

J Neurol. 2011 May;258(5):895-903. doi: 10.1007/s00415-010-5844-5.

PMID:
21153733
7.

Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.

Farrell RA, Giovannoni G.

Mult Scler. 2007 Jun;13(5):567-77. Review.

PMID:
17548434
8.

HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.

Núñez C, Cénit MC, Alvarez-Lafuente R, Río J, Fernández-Arquero M, Arroyo R, Montalbán X, Fernández O, Oliver-Martos B, Leyva L, Comabella M, Urcelay E.

J Med Genet. 2014 Jun;51(6):395-400. doi: 10.1136/jmedgenet-2014-102348.

PMID:
24748646
9.

Predictive markers for response to interferon therapy in patients with multiple sclerosis.

Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A.

Neurology. 2008 Mar 25;70(13 Pt 2):1119-27. doi: 10.1212/01.wnl.0000304040.29080.7b.

PMID:
18272865
10.

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.

Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS.

J Neurol. 2007 Jul;254(7):827-37. Review.

PMID:
17457510
11.

Optimising MS disease-modifying therapies: antibodies in perspective.

Giovannoni G.

J Neurol. 2004 Sep;251 Suppl 5:v30-v35. Review.

PMID:
15549353
12.

Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.

Jungedal R, Lundkvist M, Engdahl E, Ramanujam R, Westerlind H, Sominanda A, Hillert J, Fogdell-Hahn A.

Mult Scler. 2012 Dec;18(12):1775-81. doi: 10.1177/1352458512446036.

PMID:
22551640
13.

Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.

van der Voort LF, Kok A, Visser A, Oudejans CB, Caldano M, Gilli F, Bertolotto A, Polman CH, Killestein J.

Mult Scler. 2009 Feb;15(2):212-8. doi: 10.1177/1352458508096877.

PMID:
18805837
14.

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, Jensen PE, Koch-Henriksen N, Svejgaard A, Soelberg Sørensen P.

Eur J Neurol. 2009 Dec;16(12):1291-8. doi: 10.1111/j.1468-1331.2009.02716.x.

PMID:
19558503
15.

Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.

Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; RNF Study Group..

Clin Ther. 2007 Jun;29(6):1128-45.

PMID:
17692727
16.

Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.

Zare N, Zarkesh-Esfahani SH, Gharagozloo M, Shaygannejad V.

J Korean Med Sci. 2013 Dec;28(12):1801-6. doi: 10.3346/jkms.2013.28.12.1801.

17.

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.

Pachner AR, Cadavid D, Wolansky L, Skurnick J.

Neurology. 2009 Nov 3;73(18):1485-92. doi: 10.1212/WNL.0b013e3181bf9919.

PMID:
19884576
18.

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.

Weber F, Cepok S, Wolf C, Berthele A, Uhr M, Bettecken T, Buck D, Hartung HP, Holsboer F, Müller-Myhsok B, Hemmer B.

Pharmacogenomics J. 2012 Jun;12(3):238-45. doi: 10.1038/tpj.2011.14.

PMID:
21502966
19.

Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.

Garcia-Montojo M, Dominguez-Mozo MI, de las Heras V, Bartolome M, Garcia-Martinez A, Arroyo R, Alvarez-Lafuente R.

Eur J Neurol. 2010 Mar;17(3):470-8. doi: 10.1111/j.1468-1331.2009.02890.x.

PMID:
20050906
20.

Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic.

Zarkou S, Carter JL, Wellik KE, Demaerschalk BM, Wingerchuk DM.

Neurologist. 2010 May;16(3):212-4. doi: 10.1097/NRL.0b013e3181de4924. Review.

PMID:
20445436
Items per page

Supplemental Content

Support Center